A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

Recruiting

Phase 3

SNP-ACTH (1-39) GelA Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

Sponsor:

Cerium Pharmaceuticals, Inc.

Code:

NCT05696613

Conditions

Primary Membranous Nephropathy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SNP-ACTH (1-39) Gel

Rituximab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-27. This information was provided to ClinicalTrials.gov by Cerium Pharmaceuticals, Inc. on 2024-04-25.